# Efficacy and Safety of Avatrombopag for Treating TCP in HBV-ACLF Patients Receiving ALSS Treatment

> **NCT05382013** · PHASE4 · UNKNOWN · sponsor: **Third Affiliated Hospital, Sun Yat-Sen University** · enrollment: 60 (estimated)

## Conditions studied

- Thrombocytopenia
- Hepatitis B, Chronic
- Acute-On-Chronic Liver Failure

## Interventions

- **DRUG:** Avatrombopag
- **OTHER:** Artificial Liver Support System
- **OTHER:** Comprehensive internal medical treatment.

## Key facts

- **NCT ID:** NCT05382013
- **Lead sponsor:** Third Affiliated Hospital, Sun Yat-Sen University
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2022-04-27
- **Primary completion:** 2024-02-29
- **Final completion:** 2024-04-30
- **Target enrollment:** 60 (ESTIMATED)
- **Last updated:** 2022-11-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05382013

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05382013, "Efficacy and Safety of Avatrombopag for Treating TCP in HBV-ACLF Patients Receiving ALSS Treatment". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT05382013. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*